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Abstract For patients experiencing acute respiratory failure
due to a severe exacerbation of chronic obstructive pulmonary
disease (COPD), noninvasive positive pressure ventilation has
been shown to significantly reduce mortality and hospital
length of stay compared to respiratory support with invasive
mechanical ventilation. Despite continued improvements in
the administration of noninvasive ventilation (NIV), refracto-
ry hypercapnia and hypercapnic acidosis continue to prevent
its successful use in many patients. Recent advances in extra-
corporeal gas exchange technology have led to the develop-
ment of systems designed to be safer and simpler by focusing
on the clinical benefits of partial extracorporeal carbon diox-
ide removal (ECCO2R), as opposed to full cardiopulmonary
support. While the use of ECCO2R has been studied in the
treatment of acute respiratory distress syndrome (ARDS), its
use for acute hypercapnic respiratory during COPD exacerba-
tions has not been evaluated until recently. This review will
focus on literature published over the last year on the use of
ECCO2R for removing extra CO2 in patients experiencing an
acute exacerbation of COPD.
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Introduction
Acute exacerbations are a major cause of worsened morbidity
and mortality in COPD patients. An acute exacerbation is
characterized by a sudden change in baseline symptoms (dys-
pnea, cough and/or sputum production, respiratory status) re-
quiring a change in management or hospitalization [1, 2]. The
severity and incidence of exacerbations are related to the un-
derlying severity of COPD. Typically, exacerbations in mild to
moderate COPD can be treated pharmacologically and with
supplemental oxygen; however, exacerbations in patients with
severe to very severe COPD are often associated with acute
hypercapnic respiratory failure requiring hospitalization and
respiratory support [3]. For patients requiring respiratory sup-
port with invasive mechanical ventilation (MV), in-hospital
mortality in recent meta-analyses and observational studies
has been reported to be as high as 25–39% [4–8]. Furthermore,
patients with COPD requiring invasive MV have a higher risk
of prolonged weaning and failure to wean compared to other
causes of acute hypercapnic respiratory failure [9–11].
For COPD patients experiencing severe exacerbations
requiring respiratory support, randomized trials conducted
in the mid-1990s established noninvasive positive pressure
ventilation as an alternative method of respiratory support to
invasive MV, which reduced mortality by 50 % [12, 13]. In a
recently reported analysis of United States data from 1998–
2008 for COPD exacerbations, mortality in patients success-
fully treated with noninvasive ventilation (NIV) was only
9 % compared to 23 % for invasive MV [4]. NIV has become
the standard of care in severe exacerbations of COPD [14].
Despite continuous improvement in the application of
NIV support, 15%-26 % of patients with acute exacerbations
of COPD fail NIV support and require transition to invasive
MV [15–17]. The mortality for patients who require invasive
MVafter failing NIV has been shown to be worse than those
who are treated at the outset with invasive MV [4]. The
initial pH upon presentation is important in determining
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outcome from NIV [16, 18]. Moreover, if the pH measured
after 2 hours of NIV support is less than 7.25, the likelihood
of NIV failure has been shown to be increased [16], and in
many studies, a pH<7.20 is regarded as an indication for
intubation [19]. The primary indications of NIV failure are
hypercapnia, severe acidosis, dyspnea, increased respiratory
rate and work of breathing, i.e., indications of the inability to
ventilate CO2 [20–22].
In normal humans, the production of CO2 and its removal
are finely balanced, and homeostasis is maintained through
changes in breathing volume and rate. Normal resting CO2
production averages 200 mL/min. During acute exacerba-
tions of COPD, resting CO2 production is increased due to
additional work of breathing and increased metabolism, and
is estimated to be as much as 23% higher than normal resting
production [23]. In addition, acute exacerbations also lead to
dynamic hyperventilation which can cause a worsening of
ventilation-perfusion mismatching due to both increased al-
veolar dead space and pulmonary shunting [24]. During a
COPD exacerbation, patients develop mixed ventilatory and
hypoxic respiratory failure. The hypoxemia can be treated
with supplemental oxygen. However, this results in a further
worsening of the ventilatory failure [24, 25]. A significant
number of COPD patients with acute exacerbations, ranging
from 15 to 26 %, require ventilatory support, primarily to
assist with an increase in the ventilation of CO2.
For those patients who fail support with NIV, the need for a
higher ventilation rate through restricted airways into dam-
aged lung tissue using invasive MV leads to lung damage and
concomitant complications, such as pneumothorax and
pneumomediastinum. Reduction of ventilator volumes or
pressures to prevent these complications causes CO2 retention
and acidosis. This leads to increased dyspnea and work of
breathing, often preventing successful weaning from invasive
MV. Thus, the need for extra CO2 removal in patients with
severe COPD exacerbations occurs during support with NIV
and in the process of weaning from invasive MV to prevent
prolonged weaning or failure to wean.
Evolution of ECMO to ECCO2R
The idea of using cardio-pulmonary bypass (CPB) systems
for longer-term support of acute respiratory failure was first
attempted in adults by Hill et al. in 1972 [26]. Like its CPB
predecessor, this early form of extracorporeal support in-
volved high flows with veno-arterial cannulation. The prima-
ry goal and challenge was to replace the full oxygenation
performance of the lungs so they could be rested and allowed
to heal; hence, the term extracorporeal membrane oxygenation,
or ECMO, evolved. Although this term is often used today as a
general term for any mode of extracorporeal gas exchange, it is
in fact a misnomer when used to embody extracorporeal
respiratory support aimed primarily at supporting the CO2
removal function of the lungs.
The concept of extracorporeal carbon dioxide removal
(ECCO2R) evolved in response to early trials of ECMO
where the high incidence of adverse events and mechanical
complications relegated the therapy to only the sickest of
patients as a last ditch effort [27]. Furthermore, the high cost
and complexity of the ECMO systems limited their use to a
small number of high volume specialized medical facilities.
As experience increased with the methods of life support for
patients suffering from acute lung failure, including both
mechanical ventilation and ECMO, it was soon recognized
that a significant portion of gas exchange could be achieved
through the native lungs using less damaging control algo-
rithms for mechanical ventilation, and that in many cases,
extracorporeal gas exchange was needed more for the partial
support of CO2 removal than for oxygenation.
As the understanding of the underlying physiology
governing gas exchange in artificial membrane lungs
evolved, it was also recognized that clinically meaningful
levels of CO2 exchange could be achieved at much lower
flows than for oxygenation. By using a sweep gas of up to
100 % oxygen at high flows, the gradient in partial pressure
of oxygen and CO2 across the membranes separating the
blood from gas can be significantly higher than the gradient
across the capillary and alveolar wall in the native lungs,
which helps overcome the added resistance to diffusion of
the membrane wall and the blood boundary layer. This is due
to the steep slope in the CO2 dissociation curve in the
physiologic range of dissolved CO2 in which CO2 removal
occurs (40–45 mmHg). The slope of this curve represents the
carrying capacity of the blood for CO2 and hence the amount
of CO2 that can be removed based on the change in partial
pressure. In contrast, the slope of the oxy-hemoglobin dis-
sociation curve plateaus above an oxygen partial pressure of
100 mmHg due to the limited oxygen carrying capacity of
the blood, which restricts the amount of oxygen that can be
transferred to the blood by a gas exchanger at a given blood
flow rate.
The feasibility of ECCO2R became evident when it was
shown that oxygenation could be achieved with the lungs
without ventilation (i.e. forced inspiration and expiration),
by applying high O2 concentrations and a continuous positive
pressure. Of course, applying this form of “apneic” oxygena-
tion results in the immediate retention of CO2 and severe
acidosis. However, if CO2 removal could be achieved with
an extracorporeal gas exchanger using safer modes of opera-
tion, the lungs could be controlled using gentler conditions to
exclusively provide oxygenation, hence disassociating oxy-
genation and CO2 removal. This concept was first developed
and explored by Ted Kolobow and Luciano Gattinoni in
1977–1978 through a series of in vivo and human clinical
studies that validated its feasibility [28–31].
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Early clinical trial of ECCO2R
In 1994, Morris et al. published the results of a randomized
control study of full ECCO2R (meaning 100 % CO2 removal)
versus conventional mechanical ventilation for the treatment of
severe acute respiratory distress syndrome (ARDS). Survival in
the ECCO2R group was 33 % versus 42 % for the control
group, which was not different statistically, but in conclusion,
ECCO2R was not recommended as a therapy for ARDS [32].
This early trial of ECCO2R still depended on complex extra-
corporeal systems requiring multiple gas exchangers with high
flow resistances and large surface areas (3.5 m2), as well as the
use of occlusive roller pumps, which likely contributed to the
disappointing clinical trial outcomes. The exposure of blood to
such large fiber surface areas required high levels of
anticoagulation that resulted in significant bleeding and high
blood product requirements. Furthermore, the investigators
used a variant of apneic oxygenation for mechanical ventilation
support (low frequency positive pressure ventilation) in con-
junction with ECCO2R, which utilized peak pressures and tidal
volumes much greater than what is currently used with
ECCO2R to minimize ventilator induced lung injury in ARDS.
Partial extracorporeal CO2 removal
The approach of “partial” CO2 removal (PECOR) was first
explored by Gattinoni et al., and published in 1986 [33]. This
was an important paper because it showed that if extracor-
poreal support was used to remove only 33 % of estimated
basal CO2 production in patients maintained with non-
invasive ventilation (NIV), significant drops in tidal volume
could be achieved with relatively small decreases in PaCO2.
This method was further explored and validated in a case
study reported by Pesenti et al. in 1990 of a patient suffering
from bilateral bullous emphysema with recurrent
pneumothoraces, bilateral air leaks and pulmonary infection,
who had been on mechanical ventilation for 28 days [34].
Partial ECCO2R was used to allow the complete removal of
mechanical ventilatory support to non-invasive ventilation,
first with pressure support, then to CPAP (continuous posi-
tive airway pressure). Even though the extracorporeal system
relied on large gas exchangers and a fairly complicated
circuit, therapy was provided at a blood flow rate of only
0.4–0.6 L/min using veno-venous cannulation with small 12
Fr catheters. The rate of CO2 removal was measured to be
33–71.5 mL/min, which was estimated to be 22 % - 40 % of
the patient’s CO2 production. The remainder of gas ex-
change occurred through the lungs using noninvasive ven-
tilation. After 8 days, the extracorporeal circuit was able to
be removed, and eventually all forms of respiratory support
were suspended, and the patient was ultimately discharged
to home.
Reduction of risk associated with extracorporeal gas
exchange
Originally, the reduction of risks associated with ECMO was
approached by utilizing lower blood flow rates through the
circuit and by using veno-venous cannulation, as opposed to
the traditional veno-arterial cannulation. Arterial cannulation
increases the risks of extracorporeal support because of the
high pressures that need to be generated by the circuit pump,
which can cause leaks or ruptures and greater levels of
hemolysis. It also increases the risks of potential air embo-
lism or thromboembolism being released directly into the
central arterial blood flow. As the technology and under-
standing of extracorporeal gas exchange has improved, fur-
ther reductions in the incidence of adverse events and me-
chanical failures have been achieved by:
& Advances in hollow fiber membrane technology, in
terms of reductions in the fiber diameter and wall thick-
ness, and prevention of plasma leakage to reduce the
need for gas exchanger replacements;
& More sophisticated arrangements of hollow fiber mem-
branes which reduce priming volume, reduce resistance
to both blood and sweep gas flow through the device, and
improve the gas exchange efficiency allowing for re-
duced fiber surface area and/or circuit flow rate;
& The use of centrifugal pumps or non-occlusive pressure
controlled roller pumps, which reduces damage to the
blood (hemolysis) and the incidence of circuit rupture;
& Biocompatible coatings on the fibers and circuit compo-
nents (such as heparin), which reduce the risk of clot
formation as well as the necessary levels of systemic
anticoagulation;
& The use of single dual-lumen catheters and percutaneous
venous cannulation, which reduces the incidence of
cannulation-associated adverse events as well as the level
of patient discomfort;
& Simplifications in the system design to reduce risk of
mechanical failure and operator error;
& Use of active mixing of blood adjacent to the fibers to
increase gas exchange efficiency, which allows for re-
duced fiber surface area and/or reduced blood flow;
& Use of arterial-to-venous cannulation to eliminate the
need for a pump.
Recently published reviews of ECCO2R
Two reviews of ECCO2R technology and its clinical appli-
cations were published in 2012. Cove et al. provides an in
depth discussion of the principles behind ECCO2R and the
associated technology. It includes detailed descriptions of
several modern partial ECCO2R devices, including the
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Hemolung Respiratory Assist System (ALung Technologies,
Pittsburgh, PA), the Novalung iLA and iLA activve
(Novalung GmgH, Hechingen, Germany), and the Hemodec
DECAPsmart (Hemodec, Salerno, Italy) [35]. This paper
also reviews literature on animal experiments in the use of
dialysis to remove CO2 in the form of bicarbonate. This latter
form of extracorporeal CO2 removal remains in the very
early stages of development.
The second review article by Terragni, Maiolo and
Ranieri provides an analysis of the technological implemen-
tation and clinical applications of ECCO2R, and proposes a
new classification of modern extracorporeal support tech-
niques based on vascular access requirements, levels of gas
exchange, levels of circuit blood flow, and other technolog-
ical aspects [36•]. The classification includes a continuum of
complexity ranging from the lowest in complexity and inva-
siveness, which is likened to continuous renal replacement
therapy, to the highest in complexity and invasiveness, rep-
resentative of total extracorporeal support, or ECMO. Partial
ECCO2R is shown to fall in the low to middle range of this
continuum of device complexity and invasiveness. This pa-
per also provides a historical review of published clinical
studies of ECCO2R for the treatment of ARDS, culminating
with a discussion of the intriguing observational study pub-
lished by Terragni et al. in 2009, which showed that lung
protective ventilation strategies targeting a tidal volume below
6mL/kg, where resulting respiratory acidosis is managed with
partial ECCO2R, enhances lung protection [37]. This review
article also discusses the potential for use of ECCO2R in
COPD, stating that, “ECCO2R techniques could also repre-
sent a revolutionary tool for the approach of other clinical
situations like COPD”.
Recently published studies of ECCO2R for COPD
Until 2009, there were no published studies of ECCO2R in
the COPD population, other than a few case reports, the
earliest occurring in 1986 [38, 39]. There have been no
published prospectively conducted, randomized, controlled
trials evaluating the safety or efficacy of ECCO2R in the
COPD population. In the last year, however, two interesting
studies of ECCO2R in COPD were published, one a retro-
spective matched control study in 21 patients, 14 of which
were COPD, and the second a pilot study of a new ECCO2R
device in 20 COPD patients.
Kluge et al. reported on the first clinical study of the safety
and efficacy of using partial ECCO2R with the Novalung
iLA, a pumpless arterio-venous gas exchange device, to treat
patients suffering from acute hypercapnic respiratory failure
who were failing support with NIV [40•]. In this study, 21
patients who were treated with partial ECCO2R at the point
of failing support with NIV were compared retrospectively
to patients who had been treated conventionally with inva-
sive MV upon failing NIV. Of the 21 patients treated with
partial ECCO2R, 14 were treated due to an acute exacerba-
tion of COPD; other underlying disease conditions included
cystic fibrosis, pulmonary graft-versus-host disease, pulmo-
nary fibrosis, and bronchial asthma.
The results of this study showed that 90 % of the patients
treated with the Novalung did not require intubation and
invasive mechanical ventilatory support, and that there was
a trend in this group towards a reduced length of hospital
stay. Despite the high rate of avoidance of invasive MV, there
was no statistical difference in 28-day mortality (5/21 versus
4/21) or 6-month mortality (33 % in both groups). In addition
to demonstrating avoidance of mechanical ventilation, the
study results showed statistically significant correction of
arterial pH and PCO2, as well as respiratory rate relative to
baseline measures after 21–24 hours on ECCO2R.
While all attempts were made to match relevant parameters
in the retrospective control group, there was a statistically
significant difference between groups with respect to the aver-
age arterial partial pressure of CO2 prior to commencing
ECCO2R or MV. Additionally, there were nine patients in the
ECCO2R group who were on the lung transplant list, but none
in the matched control group. In the group of patients treated
with ECCO2R, the average PaCO2 prior to beginning ECCO2R
was 84 mmHg, whereas in the matched control group, the
average PaCO2 was only 65 mmHg prior to intubation and
invasive MV. It is plausible that this difference negatively
impacted mortality outcomes in the ECCO2R group. It is also
possible that the retrospectively identified patients were
intubated with varying criteria compared to the criteria for
beginning ECCO2R support. There were no statistical differ-
ences in all other matched parameters, including gender, age,
duration of NIV prior to failure, ventilatory parameters, respi-
ratory rate, pH, SAPS II score, or PaO2/FIO2.
The device used in this study has been reported on previ-
ously, but is unique in that it utilizes arterial blood pressure
instead of a pump to drive blood through a gas exchanger
having a surface area of 1.3 m2. This requires cannulations in
both the femoral artery and femoral vein. In earlier studies of
the Novalung iLA, there were significant complications asso-
ciated with the arterial cannulation [41]; however, these com-
plications have been reduced by limiting the catheter size. In
the current study, the arterial cannula size ranged from 13 to 15
Fr, the femoral cannula size ranged from 13 to 17 Fr, and blood
flow ranged from 0.6 to 1.8 L/min (median of 1.1 L/min).
Reduction in catheter size reduces the potential circuit flow
and hence the amount of oxygenation and carbon dioxide
removal; however, the level of gas exchange provided was
shown to be clinically beneficial in terms of correction of
arterial blood gases and avoidance of invasive MV. Reported
complications included two major and seven minor bleeding
events during the course of treatment, a pseudoaneurysm of the
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femoral artery, and one incidence of type 2 heparin-induced
thrombocytopenia. There were no acute complications due to
catheter insertion. The two major bleeding events included a
major bleed at the insertion site on the seventh day of treatment,
requiring bedside surgical repair, and in a different patient,
significant bleeding requiring discontinuation of ECCO2R ther-
apy followed by standard of care support with invasive MV.
Complications associated with intubation and invasive MV
were not available in the retrospectivelymatched control group.
Burki et al. also reported on a pilot study of partial
ECCO2R in COPD patients with hypercapnic respiratory
failure using the Hemolung Respiratory Assist System
(RAS) [42•]. The purpose of this study was to collect safety
and efficacy data for the Hemolung RAS in support of the
European regulatory approval process, and therefore, signif-
icant detail on patient status, outcome and adverse events
was collected and reported. All patients in this study had
provided written informed consent to be treated with the
Hemolung device. There were three groupings of patients
based on respiratory support status who were treated with
partial ECCO2R using the Hemolung RAS. The first group
consisted of seven patients who were receiving NIVand had
a high likelihood of requiring intubation. The second group
of two patients had failed two weaning attempts from con-
tinuous NIV support, and did not wish to be intubated. The
third group of 11 patients was already on invasive MV, and
were placed on ECCO2R to assist with weaning.
In the first group of patients, despite a mean arterial pH of
7.25 and PCO2 of 83 mmHg at baseline while on NIV, all
seven avoided intubation and mechanical ventilation. Im-
provement of blood gases was noted within 6 hours, with
mean arterial pH reaching approximately 7.36 and PCO2
falling to approximately 61 mmHg within 24 hours. Time on
the ECCO2R device ranged from 41 to 160 hours. Both
patients in the second group also avoided invasive MV but
remained on intermittent NIV support after weaning from
ECCO2R. In the third group, decreases in dyspnea and venti-
lator support were reported in several patients, with three
having been weaned at 30 days post-therapy. Only two pa-
tients were weaned temporarily while on ECCO2R therapy.
Notable was the observation that prior to initiating support
with partial ECCO2R in this group, nine of 11 patients had
already been on invasive MV for greater than two weeks, and
the two who were temporarily weaned had only been on
invasive MV for 4 and 9 days. This suggests the hypothesis
that support with partial ECCO2R following intubation may
be able to provide more clinical benefit if applied earlier,
before a COPD patient becomes ventilator dependent.
The Hemolung RAS device has a membrane surface area
of 0.59 m2, and utilizes a single veno-venous dual lumen 15
Fr catheter the can be inserted in a femoral or jugular vein.
This device was described in detail in a separate report
published in 2012 describing in vivo characterization tests
of its performance [43]. The Hemolung RAS (see Fig. 1) re-
ceived CE marking for European use and the Health Canada
license for use in Canada in February of 2013. The average
blood flows reported in the COPD study ranged from 380 to
460 mL/min. The amount of CO2 removal by the device was
also measured and reported, with an average ranging from
approximately 79 to 89 mL/min. The reported adverse events
from this study were consistent with those expected for extra-
corporeal support and central venous cannulation, as well as for
those expected in patients with severe underlying COPD
experiencing an acute exacerbation requiring noninvasive or
invasive ventilatory support.Major complications included three
major bleeding events requiring transfusion, a significant throm-
bocytopenia post-ECCO2R requiring plasma, one pneumotho-
rax, and one deep vein thrombosis. One patient died 3 hours
after initiation of ECCO2R therapy due to the catheterization
procedure that caused an undetected retroperitoneal bleed. At
30 days following therapy, all-cause mortality was 35 %.
A case report from the above reported pilot study was also
published this year by Bonin et al., detailing the experience of
using partial ECCO2R with the Hemolung in a lung transplant
candidate with very severe underlying COPD who was on
NIV support due to an acute exacerbation [44]. In this case,
partial ECCO2R was used to avoid the risks of invasive MV,
Fig. 1 Hemolung respiratory assist system
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which were substantially increased based on the history and
current condition of the patient. The patient was weaned from
NIV support while on the Hemolung (for a total of 140 hours),
received a bilateral transplant 31 days after being weaned from
the Hemolung, and was discharged 63 days later.
In a small six patient study reported by Spinelli et al. at the
33rd International Symposium on Intensive Care and Emer-
gency Medicine, the effect of the amount of extracorporeal
CO2 removal on the respiratory rate was investigated in
spontaneously breathing COPD patients with an acute exac-
erbation who were failing support with NIV [45]. Using
venovenous ECMO at a mean blood flow of 2.9 L/min, the
amount of CO2 removal was systematically modified by
varying the sweep gas flow rate. The respiratory rate was
measured at three different levels of sweep gas flow. In all six
patients, respiratory rate decreased as extracorporeal CO2
removal was increased from a mean of 28±4 breaths/min at
the lowest sweep gas flow to 8±4 breaths/min at the highest
sweep gas flow, demonstrating that the respiratory rate can
be used to titrate the amount of CO2 removal required.
Conclusions
The reduced risks of newer low-flow partial ECCO2R devices
compared to conventional ECMO have prompted the investi-
gation of their safety and efficacy in previously unconsidered
patient populations for whom supplemental CO2 removal may
have clinical benefit that outweighs the risks. These newer
technologies are well suited to acute reversible hypercapnic
respiratory failure, which occurs with highest prevalence in
the COPD population. The use of endotracheal intubation and
invasive MV, while currently the standard of care for COPD
patients experiencing acute respiratory failure who either fail
support with NIVor immediately require intubation, is associ-
ated with significant risks that increase with time on ventilation.
Risks include barotrauma and volutrauma to the lungs, airway
injuries caused by endotracheal intubation, and the develop-
ment of ventilator-associated pneumonia (VAP). The risk of
ICUmortality was found to be significantly increased in a study
of COPD patients who developed VAP compared to patients
without COPD [46]. Similarly, in a separate study of COPD
patients, VAP was shown to be an independent predictor of
increased ICU mortality [47]. In these studies, ICU mortality
for COPD patients on invasive MV who developed VAP was
60–64 %. Avoidance of invasive MV is also important from a
patient perspective. Many severe and very severe COPD pa-
tients have previously required invasive MV with prolonged
weaning experiences. Several studies have linked prolonged
invasive MV to depression, anxiety, and post-traumatic stress
disorder [48, 49].
The significant reduction inmortality achievedwith success-
ful NIV support for severe COPD exacerbations suggests that
any technique that increases the avoidance of invasive MV is
likely to be of clinical benefit. The two published studies of
using partial ECCO2R to avoid invasive MV in patients failing
NIV support demonstrated successful avoidance of invasive
MV. In the Hemolung study, measures of CO2 removal by the
ECCO2R device were reported, demonstrating that clinical
benefit is possible with CO2 removal rates less than 50 % of
basal metabolic production. CO2 removal and the concomitant
reduction of respiratory acidosis in patients with COPD exac-
erbations helps to reduce the respiratory drive and the work of
breathing associated with dynamic hyperinflation. As shown in
the study by Spinelli et al., the sweep gas flow of an ECCO2R
device can be used to control the reduction of the unassisted
respiratory rate while a patient is treated with NIV. Many
patients with severe underlying COPD have elevated baseline
levels of hypercapnia; thus, the sweep gas flow of an ECCO2R
device can be used to prevent excessive CO2 removal below
baseline levels, which can cause complications associated with
acute hypocapnia and respiratory alkalosis.
The reported results of using ECCO2R for COPD exacer-
bations are preliminary. There is insufficient information
regarding when ECCO2R should ideally be implemented
other than when NIV is failing, as evidenced by high or
increasing levels of respiratory acidosis, hypercapnia, dys-
pnea, respiratory rate and work of breathing. While the risks
of partial ECCO2R with the newer technologies are reduced
compared to ECMO, these risks must be acknowledged and
weighed against the benefits of avoiding intubation. The
reported studies on using ECCO2R during acute exacerba-
tions of COPD were limited in size. Two studies had no
control comparison, while the other had retrospectively
matched controls without complete matching of all critical
parameters. These study limitations prevent any conclusions
from being drawn regarding the clinical benefits of avoiding
invasive MV with partial ECCO2R in terms of mortality,
ICU or hospital length of stay, cost of support or other
relevant outcomes. However, the demonstrated ability to
increase avoidance of invasive MV, and certain trends in
the data for reduced hospital length of stay affirm the need
for further prospective, randomized, controlled studies. Ad-
ditionally, the need for further evaluation of the use of partial
ECCO2R to assist in the weaning from invasive MV of
COPD patients during acute exacerbations where improved
clinical benefit may be seen if extracorporeal support is
applied earlier after intubation, before ventilator dependence
develops, is suggested by the results of the Hemolung study.
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